Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Evolent Health management to meet with Oppenheimer
Meeting to be held in the Mid-Atlantic area on June 20 hosted by Oppenheimer.
Evolent Health initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mohan Naidu started Evolent Health with an Outperform rating and $28 price target.
Wells 'strongly' recommends Evolent, says Advisory Board deal unlikely
After hosting investor meetings with management, Wells Fargo analyst Jamie Stockton says he continues to "strongly" recommend shares of Evolent Health. In a research note titled "Stay Thirsty," the analyst argues that few companies in Digital Health could be "World's Most Interesting" and that Evolent "might just take the cake." While the company did not explicitly comment on the Advisory Board (ABCO) M&A speculation floated by Reuters, it stated that it has no intention of doing anything that would materially change the growth profile, Stockton tells investors. He interprets this as a "no" regarding the merger happening. The analyst adds that Evolent is talking to several dozen organizations around the next generation accountable care organization cohort and has two roughly $100M managed Medicaid opportunities. Stockton keeps an Outperform rating on Evolent with a $24-$28 price target range.
Evolent Health initiated with an Outperform at Baird
Baird analyst Matthew Gillmor initiated Evolent Health with an Outperform and a $30 price target.
Evolent Health price target raised to $35 from $30 at Baird
Baird analyst Matthew Gillmor raised his price target on Evolent Health to $35 from $30 as he believes the company is supporting a coalition of Mississippi hospitals that formed a provider-sponsored health plan and recently bid on a pending Medicaid RFP. The analyst believes investors are generally unaware of these opportunities and the awards will be announced this week, with the company well positioned to win at least one of the contracts. Gillmor reiterated his Outperform rating on Evolent Health shares.
TODAY'S FREE FLY STORIES